Heart failure with preserved ejection fraction (HFpEF) is a syndrome with multiple etiologies and varied phenotypic manifestations. Amyloidosis is a systemic disease that frequently affects the myocardium, and it may represent a specific etiology of HFpEF. The treatment of HFpEF associated with amyloidosis is not based on specific evidence, and the risk of hypotension as an adverse effect of pharmacological management is always a concern. In this context, this review addresses some strategies for controlling circulatory congestion, arrhythmias, cardiac conduction disorders, valvular heart diseases, and treatment of the specific type of amyloidosis based on available evidence as well as the latest recommendations and guidelines for managing cardiac amyloidosis.

No abstract